服务

Dr Vincent Jannin considers the advantages of delivering biologic medications, including glucagon-like peptide-1s, via oral delivery and discusses the technological strides being made towards enabling biologics to shift away from parenteral delivery. Biological therapies, more commonly referred to as biologics, have redefined the treatment landscape across multiple disease areas, from metabolic disorders to oncology. However, despite their clinical impact, the vast majority of biologics remain constrained to parenteral administration.1 This reliance on injection not only contributes to patient burden but also creates inefficiencies across healthcare delivery.

Discover how Lonza Capsugel helps you overcome durg product development challenges, accelerate timelines, and unlock new opportunities for innovation

When it comes to capsule selection, price is just one piece of the puzzle.

Sustainability is no longer just a responsibility—it’s a financial necessity.

This study proposes an innovative and scalable solution to increase oral bioavailability

Pharmaceutical formulators often face considerable challenges in maintaining the stability and bioavailability of acid-sensitive active pharmaceutical ingredients (APIs), such as peptides, proteins, and live biotherapeutics.

从感知到成像，从采样到给药，智能胶囊在治疗胃肠道疾病方面发挥着关键作用。In this briefing paper, we summarize the key findings from the GENEGUT review – exploring the latest capabilities and future developments of this exciting technology.

作为我们新型药物递送系统的指定卓越中心，Innovaform® 加速器是我们帮助……

Watch Dr. Camille Dumont and Meeta Kratz's presentation at CPHI Worldwide 2024. Explore Lonza’s Innovaform® new innovation center, dedicated to accelerating...

At Lonza, we’re driven by our purpose to enable a healthier world.